Alle Fotos(2)
Wichtige Dokumente
P6487
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit
affinity isolated antibody, lyophilized powder
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(2)
About This Item
UNSPSC-Code:
12352203
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
rabbit
Qualitätsniveau
Konjugat
unconjugated
Antikörperform
affinity isolated antibody
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Form
lyophilized powder
Speziesreaktivität
human, rat
Methode(n)
immunohistochemistry: suitable
western blot: suitable
UniProt-Hinterlegungsnummer
Lagertemp.
−20°C
Posttranslationale Modifikation Target
unmodified
Angaben zum Gen
human ... P2RY1(5028)
rat ... P2ry1(25265)
Allgemeine Beschreibung
Purinergic Receptor P2Y1 is a member of G protein-coupled receptors. The P2Y1 gene is mapped to human chromosome 3q25.2. It is present in the heart, blood vessels, prostate, testis, ovary, and neural tissue.
Immunogen
synthetic peptide corresponding to residues 242-258 of rat or human P2Y1.
Anwendung
Anti-Purinergic Receptor P2Y1 antibody produced in rabbit has been used in western blotting1:200 and immunohistochemistry at a dilution of 1:50.
Biochem./physiol. Wirkung
Purinergic Receptor P2Y1 acts as a receptor for extracellular ATP and ADP. It is essential for ADP-induced platelet activation, aggregation, and thrombosis. P2Y1 also participates in endothelial cell-based nucleotide-induced relaxation and in calcium mobilization. It serves as a potential target for the generation of new antiplatelet compounds and anti-inflammatory strategies.
Physikalische Form
Lyophilized from phosphate buffered saline, pH 7.4, 1% bovine serum albumin and 0.05% sodium azide.
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Shara Khan et al.
Diabetologia, 57(12), 2535-2545 (2014-09-12)
There is evidence that ATP acts as an autocrine signal in beta cells but the receptors and pathways involved are incompletely understood. Here we investigate the receptor subtype(s) and mechanism(s) mediating the effects of ATP on human beta cells. We
Milka Koupenova et al.
Frontiers in pharmacology, 9, 37-37 (2018-02-15)
Platelets are small anucleated cells present only in mammals. Platelets mediate intravascular hemostatic balance, prevent interstitial bleeding, and have a major role in thrombosis. Activation of platelet purinergic receptors is instrumental in initiation of hemostasis and formation of the hemostatic
J Simon et al.
Acta biologica Hungarica, 54(2), 191-201 (2003-10-11)
Since the first identification of P2Y receptor sequences in 1993, it has quickly become apparent that this family of the G-protein coupled receptors is very diverse. Members of this receptor family are activated extra-cellularly by a wide variety of adenosine
Anna Wilkaniec et al.
Purinergic signalling, 13(3), 347-361 (2017-05-19)
Abnormalities of alpha-synuclein (ASN), the main component of protein deposits (Lewy bodies), were observed in Parkinson's disease (PD), dementia with Lewy bodies, Alzheimer's disease, and other neurodegenerative disorders. These alterations include increase in the levels of soluble ASN oligomers in
Agnete Kirkeby et al.
Thrombosis and haemostasis, 99(4), 720-728 (2008-04-09)
The haematopoietic hormone erythropoietin (EPO) has neuroprotective properties and is currently being explored for treatment of stroke and other neurological disorders. Short-term, high-dose treatment with EPO seems to improve neurological function of stroke patients but may be associated with increased
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.